2315 (2315) Fair Value & Analysis

Healthcare · Market cap HK$20.7B

2 2315 2315 · HK

PriceHK$46.60

Fair ValueHK$19.85

Upside-57.4%

Quality67/100

Watch 2315 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$13.20 – HK$27.12

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price +10.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$19.90 – HK$63.50 · fair‑value band HK$13.20 – HK$27.12 · the HK$46.60 price screens above the HK$19.85 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2315 (2315) currently trades at HK$46.60, while our model-based Fair Value estimate is HK$19.85 — implying the stock looks roughly 57.4% overvalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2315 generated revenue of HK$1.6B at a net margin of 18.6%. Revenue grew 73.7% year over year. It earns a return on equity of 18.6%. The balance sheet holds a net cash position of HK$979M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.6B

Revenue growth (YoY) +73.7%

Net margin 18.6%

Return on equity 18.6%

Free cash flow HK$282M FY2025

P/E ratio 93.6

More key figures

Operating margin 30.9%

EPS (TTM) HK$0.1200

EPS growth (YoY) -51.0%

Net cash HK$979M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2315 reported revenue of HK$1.4B in FY2025 versus HK$355M in FY2021, a compound +40.4%/yr. Reported net income was HK$173M in FY2025.

Revenue +40.4%/yr

FY21 HK$355M

FY22 HK$534M

FY23 HK$717M

FY24 HK$980M

FY25 HK$1.4B

Net income

FY21 −HK$546M

FY22 −HK$602M

FY23 −HK$383M

FY24 HK$33.5M

FY25 HK$173M

Is 2315 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	449.62 MXN	-94%
Regeneron Pharmaceuticals, Inc REGN	$601.65	$577.20	-4%
UCB SA UCB	€251.70	€180.06	-28%
argenx SE ARGNF	$900.00	$390.80	-57%
Alnylam Pharmaceuticals, Inc ALNY	$303.64	$110.31	-64%
Samsung Biologics Co 207940	1,000,000 KRW	724,332 KRW	-28%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2315 (2315) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$19.85 versus a price of HK$46.60 — about −57% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2315?

Our model-based fair value for 2315 is HK$19.85 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$46.60.

What is the quality score of 2315?

2315 has a Quality Score of 67/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2315 (2315)?

2315 reported trailing-twelve-month revenue of about HK$1.6B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2315?

The net profit margin of 2315 is about 18.6%, meaning it keeps roughly 18.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.